Maintenance treatment with subcutaneous immunoglobulins in the long-term management of anti-HMCGR myopathy.

Anti-3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR) myopathy is a rare, disabling, auto-immune myopathy with necrotizing pathological features, that usually follows statin exposure. Generally, patients present with proximal muscle weakness, elevated CK levels and high titres of antibodies against HMGCR [1] that persist despite statins discontinuation, while improvement typically follows the start of immunotherapy [2].

Source: Neuromuscular Disorders - December 27, 2020 Category: Neurology Authors: Angela Zuppa, Chiara Demichelis, Giuseppe Meo, Valeria Prada, Chiara Gemelli, Maria Infantino, Mariangela Manfredi, Giampaola Pesce, Alberto S. Tagliafico, Luana Benedetti, Chiara Fiorillo, Angelo Schenone, Luca Quartuccio, Marina Grandis Tags: Case report Source Type: research